Fungal infections (mycoses) were once seen as exotic diseases, but this is changing rapidly. Although rarely life-threatening in healthy patients, fungal infections are a major problem for the immunocompromised, including HIV patients and people receiving chemotherapy for cancer. Treatment is becoming difficult due to fungal resistance to the antifungal therapy, the variety of disease-causing fungi found and the toxic effects of conventional therapy.
Now, scientists believe gamma interferon, a protein molecule produced by human cells in response to infections, may help to fight fungal infections. “Immune cells called neutrophils are rapidly recruited to the site of infection and play an essential role in fungal killing,” say Drs. Javier Capilla, Karl Clemons and David Stevens, of Santa Clara Valley Medical Center, Stanford Medical School and the California Institute for Medical Research. “Gamma interferon enhances the mechanisms of these cells to make them more potent killers of fungi.”
Tests on many fungal infections, including blastomycosis, candidosis and aspergillosis have shown that gamma interferon has beneficial effects in terms of the reduction of the fungus in the organs and on animal survival. But according to Dr Stevens, interferon is not the only answer. “Therapy using gamma interferon alone has failed to clear the fungus completely from infected tissues but it has great potential to add to conventional therapy.”
“When gamma interferon was given to mice infected with Cryptococcus along with amphotericin B, a standard antifungal treatment, the rate of cure was significantly higher than using one therapy alone. We need to look at the route of administration, the frequency of dosing and the dosage given before we can determine fully the use of gamma interferon as an adjunctive therapy.”
There is still work to be done. “We explored the possibility of using gene therapy for delivering gamma interferon into the nervous system to combat fungal meningitis. Studies of this type suggest a potential clinical use for specific gamma interferon gene therapy in the future. Treatment with gamma-interferon offers a new additional approach to treatment and it provides a new approach to treating difficult diseases. However, clinical trials must document the benefit for patients” says Dr Stevens.
Other features in the November 2007 issue of Microbiology Today include:
•Comment: Microbiology – a degree of concern (page 200)
These are just some of the articles that appear, together with all the regular features and reports of Society activities.
Lucy Goodchild | alfa
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering